<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903327</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-COV-201BR</org_study_id>
    <nct_id>NCT04903327</nct_id>
  </id_info>
  <brief_title>Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress</brief_title>
  <official_title>Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC&#xD;
      in the setting of current standard of care treatments for COVID-19 infection in hospitalized&#xD;
      subjects with acute respiratory distress syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC&#xD;
      in the setting of current standard of care treatments for COVID-19 infection in hospitalized&#xD;
      subjects with acute respiratory distress syndrome.&#xD;
&#xD;
      COVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4.&#xD;
&#xD;
      Acceptable standard of care treatments for COVID-19 include all approved or emergency use&#xD;
      authorized treatments for COVID-19, even if used off-label.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality rate at Day 28</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>All-cause mortality rate at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate at Day 60 and Day 90</measure>
    <time_frame>Baseline through Day 60 and Day 90</time_frame>
    <description>All-cause mortality rate at Day 60 and Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days through Day 28</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Number of ventilator-free days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU days through Day 28</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Number of ICU days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change in clinical status as assessed using the 11-point WHO Clinical Progression Scale (0-10, where lower score means a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygenation</measure>
    <time_frame>Baseline to Day 2, Day 4, Day 6, Day 14 and Day 28</time_frame>
    <description>Change in oxygenation as assessed using PaO2:FiO2 ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVI-MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-MSC</intervention_name>
    <description>COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells</description>
    <arm_group_label>COVI-MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Excipient solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase&#xD;
             chain reaction (PCR) or an approved antigen test of any specimen&#xD;
&#xD;
          -  Hospitalized with COVID-19-induced ARD or ARDS (any severity) with a PaO2/FiO2 (PF&#xD;
             ratio) ≤ 300&#xD;
&#xD;
          -  Requires oxygen supplementation at Screening&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current standard of care treatments for COVID-19 appear to be working and the subject&#xD;
             is clinically improving&#xD;
&#xD;
          -  A previous stem cell infusion unrelated to this trial&#xD;
&#xD;
          -  Certain medical conditions that pose a safety risk to the subject&#xD;
&#xD;
          -  Pregnant or breast feeding or planning to during the study&#xD;
&#xD;
          -  Suspected uncontrolled active bacterial, fungal, viral, or other infection&#xD;
&#xD;
          -  History of splenectomy, lung transplant, or lung lobectomy&#xD;
&#xD;
          -  Concurrent participation in another clinical trial involving therapeutic interventions&#xD;
&#xD;
          -  Expected survival or time to withdrawal of life-sustaining treatments expected to be&#xD;
             &lt;7 days&#xD;
&#xD;
          -  Has an existing &quot;Do Not Intubate&quot; order&#xD;
&#xD;
          -  Has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy)&#xD;
             expect for continuous positive airway pressure or bi-level positive airway pressure&#xD;
             (CPAP/BIPAP) used solely for sleep-disordered breathing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Royal, MD</last_name>
    <phone>(858) 203-4100</phone>
    <phone_ext>4146</phone_ext>
    <email>mroyal@sorrentotherapeutics.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

